Thomas Woiwode insider trades: Tempest Therapeutics (TPST) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
and 1 more company
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 29, 2022 | TPST | ↑ Buy | 2,118,644 | $2.36 | $5.0M | Indirect | May 3, 2022 (4d) |
| Dec 30, 2020 | GRTS | ↑ Buy | 1,347,709 | $3.71 | $5.0M | Indirect | Jan 4, 2021 (5d) |
| Oct 20, 2020 | ALGS | ↑ Buy | 200,000 | $15.00 | $3.0M | Indirect | Oct 20, 2020 (0d) |
| Mar 3, 2020 | PASG | ↑ Buy | 225,000 | $18.00 | $4.0M | By Versant Vantage I, L.P. | Mar 3, 2020 (0d) |
| Mar 3, 2020 | PASG | ↑ Buy | 225,000 | $18.00 | $4.0M | By Versant Vantage I, L.P. | Mar 3, 2020 (0d) |
| May 15, 2018 | CRSP | ↓ Sell | 44,000 | $57.99 | $2.6M | Indirect | May 17, 2018 (2d) |
| May 8, 2018 | CRSP | ↓ Sell | 1,653 | $51.45 | $85K | Direct | May 9, 2018 (1d) |
| May 7, 2018 | CRSP | ↓ Sell | 119,709 | $50.38 | $6.0M | Indirect | May 9, 2018 (2d) |
| Apr 30, 2018 | CRSP | ↓ Sell | 30,566 | $50.29 | $1.5M | Indirect | May 2, 2018 (2d) |
| Apr 27, 2018 | CRSP | ↓ Sell | 222,258 | $50.11 | $11.1M | Indirect | Apr 30, 2018 (3d) |
| Apr 24, 2018 | CRSP | ↓ Sell | 22,841 | $50.99 | $1.2M | Indirect | Apr 26, 2018 (2d) |
| Apr 23, 2018 | CRSP | ↓ Sell | 101,994 | $50.68 | $5.2M | Indirect | Apr 24, 2018 (1d) |
| Dec 22, 2017 | CRSP | ↓ Sell | 3,059 | $20.29 | $62K | Direct | Dec 27, 2017 (5d) |
| Nov 27, 2017 | CRSP | ↓ Sell | 1,900 | $20.21 | $38K | Direct | Nov 28, 2017 (1d) |
| Oct 24, 2016 | CRSP | ↑ Buy | 161,000 | $14.00 | $2.3M | Indirect | Dec 23, 2016 (60d) |
| Jul 25, 2016 | BOLD | ↑ Buy | 34,781 | $15.00 | $522K | By Versant Venture Capital IV, L.P. | Jul 25, 2016 (0d) |
| Jul 25, 2016 | BOLD | ↑ Buy | 219 | $15.00 | $3K | By Versant Side Fund IV, L.P. | Jul 25, 2016 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TPST insiders
Open-market trades in the last 12 months
About Thomas Woiwode's insider trades
Thomas Woiwode is a director at Tempest Therapeutics (TPST). Since Jul 25, 2016, Thomas has reported 8 open-market purchases worth $23.9M and 9 sales worth $27.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (29 filings), other transactions (6 filings), conversions (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TPST insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.